Assembly Biosciences Promising Candidate for Chronic Hepatitis D Virus HDV Treatment
Leading biotech company Assembly Biosciences has recently announced the selection of ABI-6250 as a promising candidate for the treatment of chronic hepatitis
United States South San Francisco Assembly Biosciences Inc Drug Administration Daredare Bioscience Inc Biosciences Inc
Source: d1softballnews.com